Mankind Pharma Peer Comparison

NSE: MANKIND | BSE: 543904

₹2,535.00

₹31.20 (1.25%)

As on 01-Oct-2026IST

Market cap

₹1,04,376 Cr

Revenue (TTM)

₹14,738 Cr

P/E Ratio

51.1

P/B Ratio

6.2

Div. Yield

0 %

Edit

	Mankind Pharma	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Lupin
Market cap (₹ Cr)	1,04,376	1,14,239	1,00,170	96,376	92,784
Revenue (₹ Cr)	14,738	28,592	33,228	34,935	29,967
Net Profit (₹ Cr)	2,055.11	4,492.20	3,169.30	3,712.74	5,551.01
Net Margin (%)	13.64	14.92	9.15	10.42	18.23
RoE (%)	13.60	18.78	8.72	10.38	28.32
Price to Earnings	51.10	25.31	31.09	25.96	16.78
Price-To-Book	6.20	4.24	2.62	2.48	3.90

Income Statement (₹ Cr)

	Mankind Pharma	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Lupin
Operating Revenue	14,737.88	28,591.70	33,227.90	34,935.29	29,966.58
Total Income	15,061.79	30,111.40	34,650.70	35,624.79	30,442.31
Total Expenditure	10,911.05	21,334.70	28,088.10	27,850.01	20,428.27
EBITDA	3,826.83	7,257.00	5,139.80	7,085.28	9,538.31
Depreciation	893.20	1,724.60	2,119.30	1,859.31	1,529.37
EBIT	2,933.63	5,532.40	3,020.50	5,225.97	8,008.94
Interest	578.61	510.20	416.30	387.88	452.37
Other Income	323.91	1,519.70	1,422.80	689.50	475.73
Exceptional Items	-129.75	-534.80	0.00	-105.51	-557.91
Profit before Tax	2,549.18	6,007.10	4,027.00	5,422.08	7,474.39
Provision for Tax	494.07	1,514.90	857.70	1,709.34	1,923.38
Profit after Tax	2,055.11	4,492.20	3,169.30	3,712.74	5,551.01

	Mankind Pharma	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Lupin
Shareholder's Funds	16,300.34	27,111.40	37,891.50	37,890.97	22,448.27
Minority Interest	-24.90	-79.70	38.90	1.76	-22.18
Non-Current Liabilities	5,011.23	7,112.50	3,145.10	2,580.33	3,200.22
Current Liabilities	6,507.25	15,711.90	16,747.40	18,039.01	12,651.24
Total Liabilities	27,754.83	50,672.60	56,576.70	58,196.15	38,146.06

	Mankind Pharma	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Lupin
Non-Current Assets	20,274.65	31,677.20	27,204.00	24,040.45	11,888.82
Current Assets	6,954.20	19,906.10	30,179.30	32,708.75	24,027.38
Total Assets	27,754.83	50,672.60	56,576.70	58,196.15	38,146.06
Total Debt*	6,021.78	11,769.50	7,734.10	7,676.20	5,910.20
Net Current Assets	446.95	4,194.20	13,431.90	14,669.74	11,376.14
Contingent Liabilities	924.77	989.90	336.14	1,358.37	1,094.02

	Mankind Pharma	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Lupin
Cash From Operating Activities	3,121.29	2,116.60	5,673.70	5,526.37	7,334.50
Cash Flow from Investing Activities	-196.42	-8,296.10	-6,549.30	-3,458.61	-3,864.59
Cash from Financing Activities	-2,952.69	5,806.90	829.00	-1,269.15	-845.87
Net Cash Inflow / Outflow	-27.82	-372.60	-46.60	798.61	2,624.04

	Mankind Pharma	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Lupin
ROCE (%)	13.24	21.39	13.75	12.76	28.86
ROE (%)	13.60	18.78	8.72	10.38	28.32
ROA (%)	7.36	10.03	5.89	6.86	16.43
EBIT Margin (%)	19.91	19.35	9.09	14.96	26.73
Net Margin (%)	13.64	14.92	9.15	10.42	18.23
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Mankind Pharma	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Lupin
Revenue Growth (%)	14.16	21.11	-0.87	9.09	28.19
EBIT Growth (%)	19.45	-8.99	-55.06	6.91	77.03
Net Profit Growth (%)	8.09	-3.14	-44.66	8.63	49.13
EPS Growth (%)	12.27	4.31	-43.29	11.88	60.86
Book Value Growth (%)	13.74	13.19	12.99	16.04	30.75

	Mankind Pharma	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Lupin
Price / Earnings	48.56	23.37	31.09	25.64	15.56
Price / Book Value	6.20	4.24	2.62	2.48	3.90
Dividend Yield (%)	0.04	0.09	0.67	0.24	0.89
EV/EBITDA	28.32	16.37	19.63	13.19	9.38
Market Cap (₹ Cr)	82,801.75	87,643.18	1,04,763.81	75,689.14	1,05,737.27

	Mankind Pharma	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Lupin
Debt to Equity	0.17	0.12	0.00	0.02	0.07
Short term debt to equity ratio	0.04	0.16	0.16	0.16	0.18
Current Ratio	1.07	1.27	1.80	1.81	1.90
Quick Ratio	0.74	0.91	1.35	1.15	1.42
Interest Coverage	5.41	12.77	10.67	14.98	17.52

	Mankind Pharma	Zydus Lifesciences	Dr. Reddy'S Labs	Aurobindo Pharma	Lupin
Debtors to sales (%)	11.74	18.94	30.47	20.31	22.04
Asset Turnover	0.53	0.64	0.62	0.65	0.89
Receivable days	39.93	33.55	103.79	33.71	51.23
Inventory Days	51.78	33.80	79.94	59.32	48.93
Payable days	111.46	149.82	84.78	148.20	205.75
Cash Conversion Cycle	-19.75	-82.46	98.95	-55.17	-105.59

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.